EntreMed Inc. (ENMD)

Oncology Corporate Profile

Stock Performance

1.3800
-0.0800

HQ Location

9640 Medical Center Drive
Rockville, MD 20850

Company Description

EntreMed is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMed's drug candidates target disease cells and the blood vessels that nourish them. The company's goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammation - processes that are vital to the progression of cancer and other diseases.

Website: http://www.entremed.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MKC-1cell cycle inhibitor1st line metastatic Breast cancerII
MKC-1cell cycle inhibitor1st line metastatic Endometrial cancerII
MKC-1cell cycle inhibitor1st line metastatic Ovarian cancerII
MKC-1cell cycle inhibitorNon Small Cell Lung Cancer (NSCLC)II
ENMD-2076aurora kinase inhibitorPlatinum-sensitive Ovarian cancerII
ENMD-2076aurora kinase inhibitorTriple negative Breast cancer (HER2+)II
EZN-4176novel androgen receptor (AR) mRNA antagonistCastrate-resistant Prostate cancer (CRPC)I
MKC-1cell cycle inhibitorLeukemiaI
ENMD-2076aurora kinase inhibitorLeukemiaI
ENMD-2076aurora kinase inhibitorMultiple MyelomaI
MKC-1cell cycle inhibitorPancreatic cancerI
ENMD-1198antimitotic agent (oral)Various cancer typesI
ENMD-2076aurora kinase inhibitorVarious cancer typesI
EZN-2968HIF-1 inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.entremed.com

Recent News Headlines

EntreMed, Inc. : EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma

1/23/2013 06:46 pm

(4-traders) Jan 23, 2013 - EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.

EntreMed, Inc. : EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma

1/23/2013 12:04 pm

(4-traders) Jan 23, 2013 - EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.

EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer

1/4/2013 05:51 pm

(Yahoo! Finance) Jan 4, 2013 - EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC).

EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer

1/4/2013 11:05 am

(Yahoo! Finance) Jan 4, 2013 - EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC).

EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer

7/25/2012 05:06 pm

(Marketwatch) July 25, 2012 - EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.

EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer

7/25/2012 12:00 pm

(Marketwatch) July 25, 2012 - EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.

ENTREMED INC Financials

5/22/2012 05:00 pm

EntreMed narrows loss

5/15/2012 01:01 pm

EntreMed Reports First Quarter 2012 Financial Results

5/15/2012 11:00 am

[PR Newswire] - ROCKVILLE, Md., May 15, 2012 /PRNewswire/ -- EntreMed, Inc. (<a href="/q?s=enmd">ENMD</a>), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ...

EntreMed keeps its listing

5/10/2012 02:03 pm

EntreMed Regains Nasdaq Compliance With Shareholders' Equity Listing Requirement

5/10/2012 11:00 am

[PR Newswire] - ROCKVILLE, Md., May 10, 2012 /PRNewswire/ -- EntreMed, Inc. (<a href="/q?s=enmd">ENMD</a>), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received ...

EntreMed names interim CEO

4/3/2012 11:01 am

EntreMed Appoints Interim CEO

4/3/2012 11:00 am

[PR Newswire] - ROCKVILLE, Md., April 3, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: <a href="/q?s=enmd">ENMD</a> - <a href="/q/h?s=enmd">News</a>), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that the Company ...

EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results

3/9/2012 12:00 pm

[PR Newswire] - ROCKVILLE, Md., March 9, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: <a href="/q?s=enmd">ENMD</a> - <a href="/q/h?s=enmd">News</a>), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the ...

EntreMed Initiates Plans for China Office

3/5/2012 07:00 pm

[PR Newswire] - ROCKVILLE, Md., March 5, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: <a href="/q?s=enmd">ENMD</a> - <a href="/q/h?s=enmd">News</a>), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has initiated ...